Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs)

Marco Fiorillo; Rebecca Lamb; Herbert B. B. Tanowitz; Anna Rita Rita Cappello; Ubaldo E. E. Martinez-Outschoorn; Federica Sotgia; Michael P. P. Lisanti

doi:doi:10.18632/aging.100983

← Back

Research Paper Volume 8, Issue 8 pp 1593—1606

Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs)

Figure 9. Bedaquiline does not stimulate a stress-response in normal fibroblasts. (A, B) Luc-reporter fibroblasts were employed to assess HIF and NFκB activation. Cells treated with 10 μM bedaquiline or DMSO control for 48 hours were analyzed by luciferase assays. Luminescence was normalized by SRB (total proteins). Bedaquiline does not activate NFκB pathway (A) in normal fibroblasts, while slightly reducing HIF activation (B) ** p<0.001, ns not significant.